<DOC>
	<DOCNO>NCT01441752</DOCNO>
	<brief_summary>The investigator perform multi-center , randomize , control , double-blind , prospective study evaluate effect chemotherapy combine without integrated TCM quality life ( QOL ) postoperative Non-small Cell Lung Cancer ( NSCLC ) patient . The investigator plan involve 600 case observation 3 year ( 300 case group ) , expect QOL postoperative NSCLC patient improve integrated TCM combine chemotherapy compare chemotherapy alone .</brief_summary>
	<brief_title>Efficacy Study Integrated TCM Combined With Chemotherapy Postoperative NSCLC Patients</brief_title>
	<detailed_description>At present high rate recurrence metastasis postoperative non-small cell lung cancer ( NSCLC ) patient one lead cause result failure treat lung cancer . More 35 % postoperative lung cancer patient stage I die 5 year due recurrence metastasis ; 5-year survival rate stage II , IIIa , IIIb 31 % , 17.9 % 11.7 % respectively . The survival rate improve 5 % adjuvant chemotherapy resection , regimen consist platinum-based two chemical medicine commend adjuvant chemotherapy treat postoperative NSCLC patient , toxicity side effect chemotherapy decrease quality life ( QOL ) patient . Literature preliminary study show traditional Chinese medicine ( TCM ) prolong survival improve QOL , high-level evidence need . The investigator perform randomize , double-blind study NSCLC patient complete resection stage I-III . Patients randomize observational group ( TCM granules plus chemotherapy ) , control group ( TCM placebo plus chemotherapy ) . The investigator observe 4 treatment period , observational group treat another 4 month integrate TCM combine western medicine treatment ( oral TCM medicine plus TCM intravenous injection ) , intervene measure control group . Regular follow-up arrange . The primary efficacy assessment : QOL ( QLQ-C30 scale ) ; Secondary efficacy assessment : ( 1 ) 2-year disease-free survival rate ; ( 2 ) disease-free survival ; efficacy assessment : ( 1 ) TCM symptom change ; ( 2 ) tumor marker ( CEA , CA-125 CYFRA21-1 ) . Toxicity , side effect security treatment assess time . The investigator expect integrate TCM combine Western medicine treatment well efficacy improve QOL patient , prolong disease-free survival time chemotherapy treatment . Therefore study provide evidence optimize promote integrate TCM combine Western Medicine treatment .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Meet diagnostic criterion primary bronchial lung cancer , pathologically cytologically confirm NSCLC ( squamouscarcinoma , adenocarcinoma , adenosquamous carcinoma large cell carcinoma ) patient ; 2 . Age &gt; 18 year old ; 3 . TCM syndromes Yin deficiency , Qi deficiency , deficiency Qi Yin , deficiency Spleen Kidney ; 4 . Physical status score ( ECOG PS ) ≤ 2 score ; 5 . Stage Ib ~ Ⅲb complete resection , chemotherapy perform 6 week resection , include tumor size &gt; 2cm stage Ia ; 6 . Blood routine : N &gt; 1.5×109/L、PLT ＞ 100×109/L , normal liver function kidney function ; 7 . Voluntarily involved clinical study sign inform consent . 1 . Suffering primary malignant tumor 5 year ; 2 . Incomplete resection uncertain take resection ; 3 . Serious disease heart , liver , kidney severe dysfunction ; 4 . Pregnancy breastfeed woman ; 5 . Mental cognitive disorder would influence judgment QOL study ; 6 . During adjuvant chemotherapy ; 7 . Being participate drug trial ; 8 . Allergy drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>